I graduated from the University of Khartoum in Sudan in 1994 as a veterinary surgeon, having attained a BA in Veterinary Science. In 1996 I started to work as a teaching assistant at the Sudan University for Science and Technology in the Veterinary medicine department and worked into general practice as a veterinary surgeon at the university clinic. In 2000 I started my Masters degree on the prevalence of Dermatophilus congolensis in bovine and finished the research after further 2 years. In 2004 I worked on a research on the incidence of Trypanosmosis transmitted by Tabanus in Khartoum state. In 2010, I started 4 years PhD on the effect of vasoactive intestinal peptide as anti-inflammatory agent on the sepsis syndrome caused by gram negative Salmonellosis.
School Research Theme:
Animal Infection and Immunity
The therapeutic potential of vasoactive intestinal peptide in human gram negative induced sepsis
Summary of Research:
Sepsis is one of the diseases that have a global importance as it had the highest death toll. And all ages are prone to the disease. It is frequently associated with Gram-negative infections and sometimes with intestinal problems although the cause of a significant proportion of cases is unknown. The therapeutic potential of VIP has been shown against infectious diseases such as experimentally induced colitis and keratitis is mice, human rheumatoid arthritis and septic shock. We are studying the role of VIP in controlling sepsis which frequently accompanies infectious disease caused by Gram-negative bacteria; it is characterised by a systemic inflammatory response syndrome following release of microbial inflammatory material from bacterial cells, especially LPS which induces a potent inflammatory response. The annual mortality rate due to sepsis in the United Kingdom is higher than the rate due to lung cancer, breast cancer and bowel cancer combined. Salmonella enterica serovars are the cause of gastrointestinal inflammation in man but several serotypes also produce a systemic typhoid disease in man or animals where sepsis is typically present in the later stages of the disease.
Dr Neil Foster
Prof Paul Barrow
Primary Funding Source:
Personal funding; Faculty for the future (Schlumberger), Gordon memorial and Sudan University for Science and Technology
- Membranes, molecules and biophysics: enhancing monocyte derived dendritic cell (MDDC) immunogenicity for improved anti-cancer therapy - C Rauch, H Ibrahim, N Foster - Journal of Cancer Therapeutics and Research 2013 2: 20
- VIP as a Potential Therapeutic Agent in Gram Negative Sepsis - H Ibrahim, P Barrow, N Foster - Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders) 2012
- Transcriptional modulation by VIP: a rational target against inflammatory disease - H Ibrahim, P Barrow, N Foster - Clinical epigenetics, 2011 – Springer